Vortex “As a clinician, I am excited about accessing the cancer biology of patient’s through CTCs. Vortex’s technology provides the best source of CTCs to aid in the diagnostic and treatment decisions we face every day.” – Dr. Jonathan Goldman, MD, Director of Clinical Trials in Thoracic Oncology, Associate Director of Drug Development at UCLA “Improving CTCs recovery along with high cellular purity while maintaining viability have tremendous value for translational research and clinical diagnostic applications. The VTX-1 holds the potential to revolutionize blood-based diagnostics.” - Pr. Massimo Cristofanilli, MD, FACP, Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine Wanda J. Cribbs, Lead Gartner Analyst Population Health & Analytics says: "Wanda's recent HRS press release really stands out. Delivering those results and having a client publicly share credit with their vendor is rare and says a lot. We at Gartner will have our eyes on Wanda in 2018"

Larry Cohen

CEO of Glycotest

Larry Cohen has over 30 year’s experience in the In Vitro diagnostic and medical device business. He has led large multinational businesses as well as venture backed start-ups. During his career, he has added value to several enterprises by introducing new products, acquiring businesses and entering new geographical markets.

Larry started his career in sales with Beckman Instruments and after a few years was promoted into marketing and introduced the company’s first product entry into the automated clinical chemistry market. He was then promoted into general management and re-located to the European headquarters in Geneva, Switzerland. He became the Director of the Europe, Africa and the Middle East which grew significantly during his leadership.

He has held senior executive positions at Instrument Laboratory (C.H. Werfen), and Ortho Clinical Diagnostics (J&J), both of which experienced significant growth during his tenure.

More recently, he has led smaller organizations to growth and successful liquidity events. He was CEO of HemoSense at its inception, which was ultimately sold to Alere, and he was President of ITC (International Technidyne Corp., a division of Thoratec)which was sold to a Private Equity group.

Larry had been CEO of SenGenix when it was formed and currently serves on the Board of Directors. He was CEO of Exalenz Bioscience , an Israeli public company developing a breath-test diagnostic technology.

Larry has attended many executive development courses over the years and has served on the boards of both “not for profit” and “for profit” companies. He has also served as President of the Biomedical Marketing Association currently known as the Diagnostic Marketing Association (DMA).

Larry Cohen - NetScientific